The immunosuppressive agent mycophenolate mofetil is a prodrug for the active compound mycophenolic acid. Following organ transplantation, it is used mostly in combination with other immunosuppressive drugs, but it has also been used as primary therapy. Although in the pivotal clinical studies the drug was given in xed doses, there has been substantial interest in the measurement of mycophenolic acid in plasma as a guide to optimizing therapy. Data have emerged which indicate that the metabolism of the compound is more complex than was originally thought and that variability in exposure to the drug, assessed by area under the time-concentration curve, is an important determinant of ef cacy.
Introduction
The measurement of immunosuppressive drugs as a guide to dose optimization has become accepted practice for patients receiving either cyclosporin or tacrolimus. 1 There are strong arguments for o¡ering routine measurements of these drugs in blood, mainly related to the di¤culty of distinguishing, by clinical criteria alone, between under-dosing and overdosing, and because the risk of signi¢cant pharmacokinetic drug interactions is high. 3 In addition, despite the serious consequences of failing to take these drugs as prescribed, non-compliance has been shown to impact on the incidence of graft rejection 4 and is one reason for continued monitoring. 5, 6 Recently, similar reasons have been advanced to justify monitoring the newer immunosuppressive agent sirolimus (rapamycin). 7 During its pivotal clinical trials the immunosuppressive agent mycophenolic acid (MPA) largely escaped the approach which had been adopted for cyclosporin and tacrolimus. The drug was given in ¢xed doses, and when it was licensed there was no recommendation to monitor concentrations as a guide to therapy. Indeed, the manufacturer of the drug promoted the view that therapeutic drug monitoring (TDM) for MPA was unnecessary. Subsequent work and plasma concentration data collected during the course of the early clinical studies have led to a reevaluation of this stance 8 and the publication of guidelines for TDM of this drug. 9 In this article I will try to summarize issues relating to the pharmacokinetics and analysis of MPA which might impact on the clinical decision to measure the drug. I will also note some issues which laboratories providing a service for the measurement of immunosuppressive drugs should take into account when deciding whether to add mycophenolic acid measurement to their routine services.
low. It is marketed as Cellcept (Roche, Basel, Switzerland). MMF is also available as an intravenous formulation. 10 Another oral formulation, the enteric coated sodium salt of MPA, is undergoing clinical trials (Myfortic, Novartis Pharma, Basel, Switzerland). MMF is usually administered in a dose of 2^3 g per day, divided into two doses.
The drug is a non-competitive inhibitor of the enzyme inosine monophosphate dehydrogenase type-2 (IMPDH-2), a key enzyme in the de novo synthesis of guanine nucleotides in T and B-lymphocytes. 11 Inhibition of this enzyme blocks the proliferation of these cells by impairment of nucleic acid synthesis and leads to a reduction in acute allograft rejection. This mechanism of action is distinct from that of cyclosporin and tacrolimus, which inhibit T-lymphocyte activation 12 and sirolimus, which inhibits cytokinedriven T-lymphocyte proliferation. 13 In the UK MMF is licensed for use in the prophylaxis of acute rejection following kidney, heart and liver transplantation, in combination with cyclosporin and corticosteroids. However, there is growing literature on the use of the drug in combination with tacrolimus, 14^16 or sirolimus, 17 as primary immunosuppressive therapy, 18^20 or as part of a steroid-free regimen. 21 It has also been used following bone marrow transplantation 22 and for the treatment of some autoimmune diseases. 23, 24 Similar to other immunosuppressive drugs, MMF therapy is associated with several adverse e¡ects. These include gastrointestinal symptoms (diarrhoea, nausea, abdominal pain and vomiting) and haematological disturbances (leukopenia, thrombocytopenia and anaemia). 25 
Pharmacokinetics
When administered orally, MMF is rapidly hydrolysed to MPA and is virtually undetectable in plasma. Even after intravenous infusion, MMF is not detected in plasma 10 min after cessation of the infusion. 26 After oral administration of MMF to healthy volunteers, the average time to peak plasma concentration of MPA (t max ) is less than 1h. A secondary peak plasma concentration may be seen about 6^12 h after administration, due to enterohepatic re-circulation of the drug. A plasma concentration pro¢le following a single oral dose, which illustrates this phenomenon, can be seen in Fig. 1 . Oral bio-availability of MPA from MMF is high, averaging about 95%. The elimination half-life averages 17 h. Distribution of MPA within whole blood results in more than 99% of the drug remaining within the plasma fraction, supporting the rationale for the measurement of MPA in plasma or serum.
The major metabolite of MPA (illustrated in Fig. 2 ) is the phenolic glucuronide, 7-O-MPA-glucuronide (MPAG). 27 This metabolite has no pharmacological activity with respect to the inhibition of IMPDH-2 activity. 11 It is renally excreted and is usually present in plasma at more than 20-to 100-fold higher concentrations than the parent compound. Since it is renally excreted, its relative concentration in plasma can rise even more in patients with renal impairment. 28 In subjects with good renal function the elimination half-life is similar to that of MPA, but as renal function declines the half-life is prolonged and may be more than 80 h. 29 Although early studies of MPA only focused on the phenolic glucuronide metabolite, recent work has shown that the metabolism of MPA is more complex. It is now known that at least two other metabolites are formed, a 7-0-glucoside and an acyl glucuronide (AcMPAG). 30 Both can be present in predose plasma samples at concentrations similar to those of MPA, but AcMPAG is the more interesting with respect to monitoring MPA. Whilst the 7-0glucoside has no in vitro inhibitory e¡ect on IMPDH-2, AcMPAG shows a very similar potency to the parent compound. 11 It has also been suggested that AcMPAG may be implicated in the aetiology of the adverse gastrointestinal e¡ects of MPA. 31 MPA is extensively bound to serum albumin. In subjects with normal renal function the free MPA fraction is only of the order of 1^2 ¢ 5% but in patients with impaire d renal function the free fraction increases, averaging as much as 7%. 32 It has been demonstrated in vitro that the pharmacological e¡ects of MPA are related to the free-fraction in plasma, rather than to the total concentration. 33 Whilst the mean fraction of the dose absorbed by the oral route as MPA is consistently high in volunteer subjects, it is substantially more variable in transplant patients. It has been reported that the area under the time^concentration curve (AUC) for MPA varies as much as 10-fold between patients receiving the same dose of MMF. 34 In addition, within-subject changes in the AUC for MPA have been noted over time following transplantation. In kidney transplant patients receiving ¢xed doses of MMF, the mean MPA AUC increased with time following transplantation. Typically, the median AUC doubled from a value of about 20 mg.h/ L at the start of therapy to about 40 mg.h/ L 4 months after the start of therapy. 35 Changes in total MPA AUC may not re£ect those for the AUC of the unbound MPA. Weber et al. studied 17 paediatric kidney transplant patients given ¢xed doses of MPA and noted that whilst the AUC for the total concentration doubled between early post-transplantation (1^3 weeks) and stable graft function (after 3 months), the AUC for the unbound drug did not change. 36 This phenomenon was attributed to the decline in mean free MPA concentration from 1 ¢ 4% to 0 ¢ 9% over the same time period. Shaw et al. have suggested that the time-related increase in MPA AUC is a re£ection of improvement in renal function. 32 In a cohort of 33 kidney transplant patients they noted that the AUC only increased in patients who, early after transplantation, had impaired renal function. As kidney function improved the AUC increased, probably because the free fraction of MPA fell, leading to reduced clearance. These ¢ndings were consistent with previous observations that renal impairment, with concomitant uraemia and raised MPAG concentrations, resulted in relatively high free concentrations of MPA. 37 Finally, in relation to the pharmacokinetics of MPA, it is important to consider the possibility of pharmacokinetic drug interactions with MPA. Transplant recipients are often maintained on multiple drug therapy, and signi¢cant changes in the kinetics of MPA caused by other drugs could be a reason for its measurement. Unlike cyclosporin, tacrolimus and sirolimus, metabolism via the microsomal CYP-450 enzyme system is a minor, perhaps, negligible pathway for MPA. 27 Thus, the substantial literature relating to pharmacokinetic drug interactions for the former drugs is little help when prescribing MPA.
A possible interaction between MPA and tacrolimus has received substantial attention. Most MPA concentration data relate to the use of MMF in combination with cyclosporin. As the use of tacrolimus and MPA increased it emerged that, for a ¢xed dose of MPA, the pre-dose MPA concentrations were higher in patients receiving their MPA in combination with tacrolimus rather than cyclosporin. 38 From this it was concluded that there was an interaction between tacrolimus and MPA leading to elevated MPA concentrations. This appeared to be con¢rmed when in vitro studies using the enzyme UDP-glucuronosyltransferase showed that tacrolimus was a more e¡ective inhibitor of the enzyme than was cyclosporin. 39 This, it was suggested, would result in reduced formation of MPAG and lead to higher MPA concentrations in patients receiving both tacrolimus and MPA. However, the original clinical study did not include a control group of patients receiving MPA without cyclosporin or tacrolimus. For cyclosporin, this was addressed in a study of 52 kidney transplant patients receiving MPA, prednisone and cyclosporin. 40 After 6 months, 19 patients continued on triple therapy, whilst 19 discontinued cyclosporin and 14 discontinued steroids. Pre-dose concentrations of MPA were signi¢cantly lower when therapy included cyclosporin. In the group in which cyclosporin was withdrawn, MPA concentrations doubled. It was speculated that cyclosporin could inhibit the production of glucuronidase enzymes by gut £ora, thus limiting the enterohepatic recirculation of MPA from MPAG. Subsequently, a rat model was used to show that animals given placebo or tacrolimus together with MPA showed a secondary MPA peak following dosing consistent with enterohepatic recirculation, whilst those receiving cyclosporin and MPA did not. 41 Cyclosporin, but not tacrolimus, decreased MPA plasma concentrations and increased MPAG AUC, suggesting that cyclosporin was inhibiting MPAG excretion into bile. It is also worth noting that in a study in which kidney transplant patients received either cyclosporin or sirolimus, plus a ¢xed dose of MPA, the concentrations of MPA were lower in the cyclosporin-treated patients. 42 A reduction in the production of glucuronidase enzymes released from anaerobic bacteria in the gut, leading to a smaller contribution of the enterohepatic recycling of MPAG to MPA, has also been suggested as the underlying mechanism for interactions with some antibodies. 34 Metronidazole alone and in combination with nor£oxacin has been shown to reduce MPA and MPAG AUC by more than 30%.
Other pharmacokinetic interactions have been reported, including a decrease of MPA AUC by cholestyramine and antacids. 26 Concomitant therapy with cholestyramine is not recommended, and if antacids containing magnesium or aluminium hydroxides are needed they should be administered separately from MMF.
It is clear from the kinetic data accumulated so far that there is a complex interplay between total and free concentrations of MPA, in£uenced by renal function and other drug therapy, which may not be readily appreciated by measurement of total MPA alone. At the very least, these factors need to be considered in the interpretation of MPA measurements.
Measurement
Compared with the two current mainstays of immunosuppressive drug therapy, cyclosporin and tacrolimus, the measurement of MPA appears to be relatively simple. This is because pre-dose concentrations consistent with e¤cacy are substantially higher, of the order of 1mg/L or more, and a chromatographic assay is easier to perform than for either cyclosporin or tacrolimus. However, some methodological problems are emerging which might impact on routine monitoring.
The recommended matrix for the measurement of MPA is plasma from EDTA anticoagulated whole blood, 8 allowing a single sample to be collected for the measurement of whole blood cyclosporin, tacrolimus or sirolimus and plasma MPA from a centrifuged aliquot of the whole blood sample. However, the measurement has also been validated in my own laboratory using serum, which was found to be equivalent to plasma.
There are a number of published high-performance liquid chromatography (HPLC) methods for the measurement of MPA and MPAG. 43^47 All these methods are suitable for routine monitoring of MPA and some have su¤cient sensitivity to measure the drug in ultra¢ltrate samples so that free (unbound) concentrations can be determined. Recently, the measurement of the acyl glucuronide of mycophenolic acid (AcMPAG) has been described. 48 The acyl glucuronide is not available commercially, and has been quantitated as MPAG equivalents.
An immunoassay for MPA, based on the enzymemultiplied immunoassay technique (EMIT, Dade Behring) was introduced in 1998. 49 This assay can be implemented easily on a variety of clinical analysers and has performance characteristics suitable for routine monitoring of MPA, the calibration range being 0¢5^15 mg/L. Concentrations of MPA in clinical samples assayed by the EMIT assay are generally higher than those measured by HPLC 50,51 although one group found a negligible di¡erence between the two techniques. 52 On average, the di¡erence between the immunoassay and a chromatographic assay result is about 20% but does vary with the time the sample was collected relative to the last dose, a larger di¡erence being seen about 2^4 h after dosing. 51 It has been established that the di¡erence between results produced by the EMIT assay and those of a chromatographic technique is due to cross-reactivity of the antibody used in the immunoassay with AcMPAG. 53 The antibody does not cross-react with the phenolic glucuronide, but there is cross-reactivity with the pro-drug MMF. 54 Cross-reactivity with MMF could bias results if samples were collected shortly after, or during, an intravenous infusion. It is worth noting that AcMPAG has been shown to be unstable in plasma samples. 53 Whether sample stability is an issue serious enough to warrant special conditions for sample storage and transport has not yet been established, although stabilization with phosphoric acid has been recommended.
The performance of the two assay techniques currently available can be compared by reference to the ¢ndings of the International Mycophenolate Pro¢ciency Testing Scheme. 55 Data from this scheme for the measurement of MPA in samples spiked with the drug to known concentrations suggested a negligible bias of about 2%. However, for pooled samples from patients who had received MMF, the median MPA concentration was 23% higher by the immunoassay. Typical data are shown in Fig. 3 .
Clinical studies
The rationale for using MMF is based on several multicentre clinical trials in kidney 56^59 and heart transplant patients. 59 The studies in kidney transplant patients, each of which included about 500 patients, examined the e¡ect of MMF in doses of either 2 g or 3 g per day, added to an immunosuppressive regimen of cyclosporin and corticosteroids. The European study 57 was placebo-controlled, whereas the US 56 and Tricontinental 58 studies compared the use of MMF against the use of azathioprine. At 6 months posttransplantation all three studies showed signi¢cant trends for the reduction of biopsy-proven rejection and a reduced need for anti-rejection therapy. Whilst the patients receiving the higher dose of MMF su¡ered less acute rejection, adverse e¡ects were noted more frequently. The heart transplant study enrolled over 600 ¢rst heart transplant patients and randomized them to receive MMF (3 g per day) or azathioprine together with cyclosporin and corticosteroids. The use of MMF resulted in a signi¢cant reduction in 1-year mortality and the need for anti-rejection therapy. There was a non-signi¢cant trend for fewer severe acute rejection episodes amongst the MMF-treated patients.
It was anticipated from the kidney transplant studies that a reduction in acute graft rejection, an important factor in the development of chronic graft loss 60 would have a signi¢cant impact on long-term graft survival. Based on follow-up data from the European 61 and US studies, 62 this has proved di¤cult to show. The 3-year prospective follow-up of patients in the European study showed only a non-signi¢cant trend towards improvement in graft survival for those who had received MMF but did con¢rm the major e¡ect that acute graft rejection had on graft loss by 3 years post-transplant. Similar data for the US study did not show any improvement in graft survival. However, a study of data from the US Scienti¢c Transplant Registry, based on the results from over 10 000 adult kidney transplant patients who received MMF as part of their immunosuppressive regimen, has now been completed. 63 This analysis was able to demonstrate a positive e¡ect of MMF therapy on long-term graft survival. The most important variable leading to a signi¢cant MMFassociated reduction in graft loss was a reduction in acute rejection episodes.
The combination of MMF with tacrolimus therapy has also proved e¡ective following kidney transplantation. In a randomized, multicentre, three-way study in which patients on the same maintenance corticosteroid regime received tacrolimus plus azathioprine, cyclosporin plus MMF, or tacrolimus plus MMF, the latter regimen was associated with the lowest rate of steroid-resistant rejection. 14 In a dose ranging study of MMF, kidney transplant patients were randomized to receive tacrolimus and azathioprine, or tacrolimus and either 1 or 2 g MMF per day. 15 At 1 year following transplantation the incidence of biopsy proven rejection was identical in the azathioprine-and MMFtreated patients receiving 1g per day (32¢2%), but was substantially lower in the MMF-treated patients receiving 2 g per day (8¢6%). However, those receiving the higher dose of MMF had to have their doses reduced to 1¢5 g per day by 6 months following transplantation due to adverse e¡ects, mostly gastrointestinal. Whilst there is a report of MMF therapy in combination with sirolimus following kidney transplantation, the design of the study did not include a control group which did not receive MMF. 17 Ann Clin Biochem 2002; 39: 173-183 Figure 3 . Data from the International Mycophenolate Prociency Testing Scheme for the measurement of MPA in pooled samples from patients who had received MMF following either kidney (K) or lung (L) transplantation. The data are the median and interquartile range for centres using either high-performance liquid chromatography (HPLC) or EMIT immunoassay. Overall, the median difference between the two assay techniques was 23%. EMITˆenzyme multiplied immunoassay technique.
Finally, one group has reported on the use of MMF as primary immunosuppressive therapy. In a pilot study involving 32 elderly patients who received kidney grafts from elderly cadaveric donors, MMF was prescribed at a starting dose of 2 g per day. 20 The incidence of acute rejection was under 20%; all episodes responded to conversion to cyclosporin or the addition of cyclosporin to reduced MMF dose. In a second pilot study the same group switched 46 kidney transplant patients, who were at least 1 year post-transplant and had stable renal function, from cyclosporin to MMF. 18 Whilst renal function improved, there was an unacceptable incidence of acute rejection (10¢9%), although the authors could not rule out the possibility of underdosage with MMF. Follow-up data in these patients for an average of over 2 years was encouraging. 19 When dosed to achieve pre-dose MPA concentrations in the range 2^4 mg/L, there were trends for continued improvement in renal function, reduction in the need for antihypertensive therapy and an improvement in lipid pro¢le.
Thus, MMF is ¢rmly established as an e¡ective drug in the prophylaxis of acute graft rejection. Its use in combination with other immunosuppressive drugs may even contribute to the development of treatment protocols free from nephrotoxicity. 64 The next topic to consider is whether there is a usable relationship between MPA concentrations and clinical e¤cacy.
Concentration/effect relationship
For cyclosporin, tacrolimus and sirolimus the usual approach to monitoring is to measure the drug in a pre-dose (trough) sample. This is despite the fact that samples described as`trough'are often the most unreliable samples collected. This is because the time between sample collection and the last dose may di¡er substantially, especially when samples are collected at outpatient clinics at variable times throughout the day. A debate, centred around cyclosporin, has been in progress for over a decade as to whether the AUC is a more useful parameter to measure than the trough concentration, using either a full or an abbreviated AUC. 65 Despite recent evidence that AUC measurement may be superior, 66,67 several factors limit the application of AUC measurements, such as cost of additional sample analyses and the logistics of collecting multiple samples. As a consequence of the long-standing interest in the application of AUC measurements to cyclosporin monitoring, it was logical that some of the data collected during the early clinical investigations of MMF should be subjected to a similar analysis. The results were of su¤cient interest to prompt prospective studies which have yielded some promising ¢ndings.
Retrospective analysis of MPA AUC data from an early study of MMF in Japanese patients receiving the drug following kidney transplantation noted an association between low AUC and the incidence of rejection. 68 Subsequent studies demonstrated a relationship between the natural logarithm of AUC and graft rejection, which showed superior discrimination between the incidence of rejection and no rejection than did the natural logarithm of pre-dose concentration and rejection. 35 To assess whether a ¢rm relationship between MPA AUC and e¤cacy could be established, a prospective, concentration-controlled study in kidney transplant patients was performed. 69 In this study 150 recipients of cadaveric kidney grafts receiving cyclosporin and prednisone were randomly allocated to receive MMF in doses designed to produce one of three target AUC measurements. During the 6 months following transplantation MPA AUC was measured nine times at a central laboratory and the MMF dose was adjusted in a double -blind manner using a coded system. Patients received MMF doses tailored to achieve AUC measurements of 16¢1, 32¢2 or 60¢6 mg.h/L. MPA was measured using an HPLC assay. The primary end-point of the study was the incidence of biopsy-proven rejection within the 6 months of the study. There was a highly signi¢cant relationship between the MPA AUC and the incidence of rejection; in the low, intermediate and high AUC groups the incidence was 27¢5%, 14¢9% and 11¢5%, respectively. However, it should be noted that the target AUC values were exceeded in each group. At week 20, the mean values for each group were 27¢6, 54¢8 and 96¢7 mg.h/ L. There was also a much higher incidence of premature withdrawal from the study as MPA AUC increased; 7¢8%, 23¢4% and 44¢2% for the three groups, respectively.
In the above study, the ¢nal six AUC measurements were estimated using an abbreviated sampling strategy based on samples collected at the following time points: pre-dose and then 20, 40, 75 and 120 min after dosing. A previously validated algorithm was then used to estimate the full AUC 0^12h . 69 Others have also experimented with the development of limited sampling strategies to estimate AUC, using samples collected pre-dose, 1, 3 and 6 h after dosing 70 or at 1, 2 and 6 h after dosing. 71 Algorithms which include samples collected 6 h after dosing are, of course, more di¤cult to implement in an outpatient setting, but may be more reliable when samples are collected from patients who have not fasted. 72 The application of an abbreviated pro¢le measured over a period of 2 h is illustrated in Fig. 4 .
Other groups have also noted a relationship between MPA AUC and the incidence of rejection, based on HPLC measurements of MPA. In a study of paediatric kidney transplant recipients, AUC measurements below 30 mg.h/L were more frequently associated with graft rejection. 27 Comparable data for the pre-dose concentration were associated with concentrations below 1 mg/ L. However, the relationship with graft rejection was less well de¢ned for predose concentrations, compared with AUC measurements, when assessed by receiver-operated characteristic (ROC) curves. Use of ROC curves is an established method to evaluate the sensitivity and speci¢city of a biological test. 73 Some studies have con¢ned themselves to the more traditional approach of trough concentration monitoring. One of the most widely quoted is a study of heart transplant patients receiving tacrolimus and MPA. 74 In the initial part of this study, retrospective analysis of data from 15 patients suggested that predose concentrations of MPA (measured by the EMIT assay) in excess of 3 mg/L were not associated with graft rejection. The authors then went on to test this cut-o¡ point in a prospective study of 30 patients in whom pre-dose MPA concentrations were targeted in the range 2 ¢ 5^4 ¢ 5 mg/L. Three patients su¡ered an episode of rejection, at which time MPA concentrations were all below 1¢5 mg/ L. In a larger study of more than 200 heart transplant patients receiving either cyclosporin or tacrolimus augmented with MMF therapy, the incidence of signi¢cant rejection (53A using the International Society for Heart and Lung Transplantation criteria) 75 was studied in relation to pre-dose MPA concentrations. 76 Again, the EMIT assay was used to measure MPA. Within the ¢rst year after transplantation there was a signi¢cant decrease in rejection episodes if MPA concentrations (the authors actually said MMF concentrations!) were 52 mg/L.
Pre-dose concentration monitoring has also been applied in a small study of patients receiving MMF following stem cell transplantation. 77 The 14 patients were receiving cyclosporin and prednisolone when acute graft versus host disease was diagnosed. MMF was administered in a dose of 1^3 g daily and MPAwas measured by HPLC. The median MPA concentration in patients responding to therapy was approximately 1mg/L.
A consensus on MPA concentrations and adverse e¡ects has not emerged. In the concentrationcontrolled study, 78 whilst there was no statistical association between MPA AUC or pre-dose concentrations and adverse events, MMF dose was signi¢cantly related to withdrawal from the study because of adverse events. It is possible that measurement of the AcMPAG metabolite could help to clarify this issue. 31 Grossly elevated pre-dose MPA concentrations (410 mg/L) have been associated with serious adverse e¡ects and measurement of high MPA concentrations has proved useful in the di¡erential diagnosis of a complex clinical situation. 29 Recently, high concentrations measured 30 min after dosing (averaging over 30 mg/L) were associated with adverse e¡ects. 79
Factors impacting on therapeutic drug monitoring
On the basis of the published data summarized above, are there good reasons for monitoring MPA? Granted, me recommending TDM for a drug is a bit like an insurance salesman extolling the virtues of personal insurance, but there are several features of this drug which suggest that measurement may help to improve the clinical outcome:
. There are within-patient and between-patient di¡erences in the pharmacokinetics of the drug which are altered by common clinical conditions a¡ecting transplant patients. . There is the potential for pharmacokinetic drug interactions. . Adverse e¡ects caused by MPA may be di¤cult to distinguish from other causes on clinical grounds alone. . Long-term patient compliance with the medication may be erratic.
However, there are also several caveats, mostly relating to analytical methodology, that should be borne in mind:
. The current immunoassay cross-reacts with the AcMPAG metabolite. . The immunoassay gives no measure of MPAG.
. Not all HPLC assays are validated or calibrated to measure MPAG, and few centres have an assay for the measurement of AcMPAG. . There is no commercial source of AcMPAG. . Instability of the AcMPAG metabolite may cause erroneous results for the measurement of MPA. . The clinical signi¢cance of measurements of these metabolites is still not established. . Measurement of free-MPA concentrations, technically more di¤cult than total concentrations, may improve the value of monitoring. . The drug is most often used in combination with primary immunosuppressive therapy, such as cyclosporin, so MPA concentrations must be interpreted in association with these other drug concentrations.
Despite these imponderables, on balance, I favour total plasma MPA concentration measurement being made available. Even though TDM adds to the cost of an already expensive therapy, transplanted organs are a very precious resource and laboratory tests that have the potential to minimize graft loss or the serious morbidity associated with immunosuppression should be exploited to their full potential. Although my laboratory receives relatively few requests for this measurement (fewer than 30 requests per month during 2001), there is a growing demand for its provision. It would be wise for those in this ¢eld to acquaint themselves with the methodological requirements and the speci¢c problems of applying it to their own clinical setting. A service using either HPLC or the immunoassay would be relatively expensive to provide on the basis of the current sample numbers. Cost will certainly be an important consideration when deciding whether to establish an on-site assay or to send samples to a central laboratory o¡ering the assay. At present, there is no rationale for establishing a service for the measurement of unbound MPA concentrations since there are no validated data on which to apply the results. The interpretation of total MPA plasma concentrations is di¤cult, not least because the knowledge base is expanding at a rapid pace. It is also necessary to consider the concentrations of other co-prescribed immunosuppressive drugs, such as cyclosporin. 80 My current practice is to use the EMIT immunoassay, supplemented on occasions with an HPLC assay for the measurement of MPA and MPAG, especially when the patient has severe renal impairment. Anyone o¡ering a service for the measurement of MPA should be prepared to enter into a close dialogue with their clinical colleagues to maximize the information obtained from such measurements, and should not expect to use`o¡ the shelf ' reference ranges.
Conclusions
Although MPA has been in clinical use following organ transplantation for a relatively short time, its measurement in plasma has been studied extensively. I have tried to summarize the most pertinent ¢ndings of interest to laboratories with the ability to o¡er TDM services in this area. I have not dealt with pharmacodynamic monitoring since, although there are some fascinating ¢ndings on the measurement of IMPDH-2 activity, the methodology is less robust and less well documented. 19,81^84 The pharmacokinetic data suggest a complex picture in which some of the factors likely to modify the e¤cacy and toxicity of the drug are re£ected by measurements of the drug, or its metabolites, in plasma.
An essential point to remember when assessing the rapidly evolving literature on the measurement of MPA is that the key studies were performed in kidney transplant patients receiving cyclosporin and that MPAwas measured by HPLC. Numerical values for AUC and pre-dose MPA may di¡er from those produced by the currently available immunoassay, and may have a di¡erent signi¢cance in the context of other transplant indications or other immunosuppressive therapy.
The data from the concentration-controlled study are a useful starting point for assessing whether dose changes are needed in an individual patient receiving MPA as secondary immunosuppressive therapy. If a full or abbreviated MPA AUC can be measured, then values below 20 mg.h/ L are unlikely to be e¡ective; the comparable ¢gure for a pre-dose sample is about 1mg/L. These data relate to measurements made by HPLC in samples from patients also receiving cyclosporin. There are too few data on the use of MPA as primary therapy to give recommendations on target concentration ranges, although they are likely to be higher than when the drug is used in association with other immunosuppressives. It is also likely that, when used as primary therapy, the interpretation of MPA concentration data will be simpler.
Finally, the reviews and recommendations for assessing MPA therapy by Shaw and co-workers are a particularly valuable source of information. 34,85^89 
